Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Filomena Caiaffa

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Orphanet Journal of Rare Diseases|November 4, 2022
Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)Federico Spataro, Fabio Viggiani, Domenico Giorgio Macchia, et al.
Journal of Asthma and Allergy|March 3, 2021
Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype ExpressionCorrado Pelaia, Claudia Crimi, Alida Benfante, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 22, 2021
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter StudySanti Nolasco, Claudia Crimi, Corrado Pelaia, et al.
ERJ Open Research|November 1, 2023
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitisAndrea Portacci, Raffaele Campisi, Enrico Buonamico, et al.
Frontiers in Immunology|July 17, 2023
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational studySanti Nolasco, Andrea Portacci, Raffaele Campisi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 5, 2021
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysisDanilo Di Bona, Claudia Crimi, Angela Maria D'Uggento, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 11, 2024
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With MepolizumabDanilo Di Bona, Massimo Bilancia, Claudia Crimi, et al.
Frontiers in Allergy|April 4, 2025
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a <i>post hoc</i> analysis from the ANANKE studyLuisa Brussino, Maria Aliani, Elena Altieri, et al.
Frontiers in Immunology|April 17, 2023
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polypsCorrado Pelaia, Alida Benfante, Maria Teresa Busceti, et al.
Journal of Asthma and Allergy|April 2, 2024
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE StudyPaolo Cameli, Maria Aliani, Elena Altieri, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Orphanet Journal of Rare Diseases|November 4, 2022
Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)Federico Spataro, Fabio Viggiani, Domenico Giorgio Macchia, et al.
Journal of Asthma and Allergy|March 3, 2021
Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype ExpressionCorrado Pelaia, Claudia Crimi, Alida Benfante, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 22, 2021
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter StudySanti Nolasco, Claudia Crimi, Corrado Pelaia, et al.
ERJ Open Research|November 1, 2023
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitisAndrea Portacci, Raffaele Campisi, Enrico Buonamico, et al.
Frontiers in Immunology|July 17, 2023
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational studySanti Nolasco, Andrea Portacci, Raffaele Campisi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 5, 2021
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysisDanilo Di Bona, Claudia Crimi, Angela Maria D'Uggento, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 11, 2024
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With MepolizumabDanilo Di Bona, Massimo Bilancia, Claudia Crimi, et al.
Frontiers in Allergy|April 4, 2025
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a <i>post hoc</i> analysis from the ANANKE studyLuisa Brussino, Maria Aliani, Elena Altieri, et al.
Frontiers in Immunology|April 17, 2023
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polypsCorrado Pelaia, Alida Benfante, Maria Teresa Busceti, et al.
Journal of Asthma and Allergy|April 2, 2024
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE StudyPaolo Cameli, Maria Aliani, Elena Altieri, et al.
Pageof 5